CTLA4 and melanoma: The most recent clinical guidelines on melanoma management consider the anti-PD-1 agents nivolumab and pembrolizumab, alone or in combination (nivolumab) with the anti-CTLA-4 agent ipilimumab, as first-line options to treat unresectable stage III (locally advanced) and IV (with distant metastases) melanoma [80].